Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT05424315

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05424315
Other papers using this trial's data
  • Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients - DACAMI (a randomized controlled clinical trial) International journal of cardiology, 2023-05-15 DOI, PubMed 36889650

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05424315. Randomized; quadruple masking; primary purpose prevention. Start 2021-10-01 (actual); primary completion 2022-04-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients
Acronym
DACAMI
Condition
Anterior MI
Intervention (Drug)
Dapagliflozin 10mg
Intervention (Drug)
Glucose Tab
Lead sponsor
Omar Younis (class: other government)
Collaborator
Ain Shams University (class: other)

Record details

Record id
cardio:ct-nct05424315
Content hash
9242e3936902a22b72e4dd54942341f643bb683e151c2f9a74b7e75eb7cff320